First Patient Dosed With CYAD-211, a Potential CAR T-cell Therapy

First Patient Dosed With CYAD-211, a Potential CAR T-cell Therapy

283834

First Patient Dosed With CYAD-211, a Potential CAR T-cell Therapy

The first patient has been dosed in Celyad Oncology’s Phase 1 clinical trial evaluating CYAD-211, an investigational donor-derived CAR T-cell therapy for treating relapsed or refractory multiple myeloma. The IMMUNICY-1 trial (NCT04613557) intends to recruit 12 patients who received two or more prior lines of treatment, including an immunomodulatory agent and a proteasome inhibitor. Enrollment is ongoing in Belgium and the U.S. “Dosing the first patient with CYAD-211 marks another major milestone to systematically advance…

You must be logged in to read/download the full post.